WG
STML

Winton Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Winton Group’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,071
Closed -$105K – 1866
2019
Q3 		$105K Buy
+10,071
New +$132K ﹤0.01% 1460

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Winton Group's STML Position: Q4 2019 in Review

Winton Group sold out of Stemline Therapeutics, Inc. (STML) in Q4 2019, closing a stake of 10,071 shares — an estimated $105K sold.

Winton Group first reported a position in STML in Q3 2019 and held it in 1 quarter. The position peaked at $105K in Q3 2019. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

  • Winton Group reported no remaining Stemline Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Winton Group sold 10,071 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $105K.
  • Winton Group first reported a position in Stemline Therapeutics, Inc. in Q3 2019 and held it in 1 quarter.
  • Winton Group's Stemline Therapeutics, Inc. position peaked at $105K in Q3 2019.
  • 99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on Winton Group's 13F filing for Q4 2019, filed 13 Feb 2020.